Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapies for liver diseases and viral infections. Its core programs target chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections. The company’s pipeline includes pevifoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections, alongside preclinical oligonucleotide programs. Aligos is still pre-commercial, so its business is centered on research, clinical development, external funding, and potential future partnerships rather than product sales.

−3 982,4 %

−1 106,7 %

−39,5 %

3.90

3.90

— Aligos Therapeutics, Inc.
%
Clinical-stage drug candidates0% Lead therapeutic programs in HBV, MASH/obesity, and coronavirus infections that are being advanced through preclinical and clinical development.
Oligonucleotide platform0% siRNA and ASO-based discovery and development capabilities used to create liver-targeted antiviral and metabolic disease therapies.
Licensed enabling technologies0% Proprietary BNA and GalNAc chemistries licensed to improve potency, pharmacokinetics, and liver delivery.
Collaboration and contract revenue100% Revenue from research and development services and prior collaboration arrangements while the pipeline remains pre-commercial.

Aligos does not sell approved medicines, so its current revenue comes from collaboration agreements and third-party...

  • Collaboration partnersprimary

    Pharma and biotech partners that provide upfront, milestone, or shared-development funding for pipeline programs.

  • Government and public health fundersprimary

    NIH, NIAID, and related agencies funding coronavirus studies and other externally supported research.

  • Contract research customerssecondary

    Third parties purchasing R&D services that generate contract revenue while the company remains pre-commercial.

  • Future specialty healthcare providersemerging

    Hepatologists, infectious disease specialists, and treatment centers that would prescribe approved therapies if development succeeds.

Aligos is headquartered in the United States and its business is primarily managed from there...

  • •United States is the company’s home market and operating base
  • •NIH/NIAID funding supports U.S.-based coronavirus research
  • •United Kingdom platform-trial activity supports ALG-097558 development
  • •Clinical and nonclinical work is outsourced across specialized vendors
  • •No meaningful commercial geography yet because assets are pre-commercial

Aligos’ strategy is to advance a small number of differentiated, potentially best-in-class drug candidates in liver...

01
Advance pevifoscorvir sodium in chronic HBVmedium-term

HBV is a core value driver and a major unmet medical need where clinical success could validate the platform.

02
Progress ALG-055009 in MASH and obesitymedium-term

This expands the pipeline into a large metabolic disease market and diversifies the company beyond antivirals.

03
Leverage public funding for coronavirus programsshort-term

External funding lowers cash burn and supports continued development of ALG-097558 without relying solely on equity capital.

04
Preserve optionality through partnershipsmedium-term

Collaborations can provide capital, development expertise, and commercialization access for a pre-commercial biotech.

Aligos faces the classic risks of a clinical-stage biotech: no approved products, no product sales, and a long path to...

critical

Clinical development failure

The company’s value depends on proving safety and efficacy for a small number of drug candidates.

Scope
Pevifoscorvir sodium, ALG-055009, ALG-097558
Materiality
high
high

Need for additional capital

The company expects continued losses and has stated that existing resources may not be sufficient beyond the near term.

Scope
Corporate funding and pipeline advancement
Materiality
high
high

Dependence on external funding and collaborations

Coronavirus development is partially funded by NIH/NIAID and platform-trial support, which may not continue.

Scope
ALG-097558
Materiality
medium
high

Competition from larger biopharma companies

Competitors may reach approval faster, have stronger IP positions, or offer better efficacy and safety.

Scope
HBV, MASH, antiviral markets
Materiality
medium
medium

Regulatory and reimbursement uncertainty

Even successful candidates must clear lengthy approval pathways and future pricing/reimbursement hurdles.

Scope
Future commercialization
Materiality
medium
Accrued research and development expenses
Affects operating expenses and period-to-period comparability
Collaboration and contract revenue recognition
Can create lumpy quarterly revenue and margin patterns
Fair value of warrants
Can distort bottom-line results and EPS-like metrics
Going concern assessment
Important for liquidity analysis and financing risk

ALUMIS INC.

ALMS · Pharmaceutical Preparations

AGIOS PHARMACEUTICALS, INC.

AGIO · Pharmaceutical Preparations

BIOVIE INC.

BIVI · Pharmaceutical Preparations

Eledon Pharmaceuticals, Inc.

ELDN · Pharmaceutical Preparations

Apogee Therapeutics, Inc.

APGE · Biological Products, (No Diagnostic Substances)

Elicio Therapeutics, Inc.

ELTX · Pharmaceutical Preparations

: 11/08/2026